KA Kineta Inc Net earnings per share growth forecast for next year

Graphic logo of Kineta Corp (KA)

EPS outlook for next year demonstrates the impact of the immuno-oncology ecosystem, which creates a closed scientific cycle for B2B partnerships with pharma behemoths. The value of 0.00 reflects this status, which is based on the potential for global sales of patented drugs. Meanwhile, production risks are minimized by outsourcing drug manufacturing to external specialized biopharmaceutical plants for Kineta, Inc. (KA).

Kineta Corp (KA): Expected net earnings per share growth next year from 04/28/2023 to 09/28/2024

Financial and market metric breakdowns for kinetabio.com (KA)

- stock quotes and analyst forecast:
Stock Quotes Kineta Bio|KA - Analyst Consensus Forecast
- market capitalization data:
Market Value Kineta|KA - Business Value
- company book value details:
Net Assets per Single Share Kineta|KA - Total Stockholders' Equity|Market Cap to Net Assets Ratio kinetabio.com|KA - Company Balance Sheet Assets
- debt obligations and liquidity statistics:
Total Debt to Equity Ratio Kineta, Inc.|KA - Long-Term Loans to Capital Ratio|Short-Term Debt to Capital Kineta|KA - Aggregate Debt Obligations|Debts to Book Capitalization Kineta|KA - Long-Term Debt|Company Short-Term Debt Kineta|Quick Ratio kinetabio.com
- net income and valuation ratios data:
KA - Net Profit|Expected Profit Kineta, Inc.|KA - Market Cap to Net Income|Projected Price to Earnings Kineta, Inc.|KA - Price to Earnings Adjusted for Growth Rate|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Kineta|KA - Operating profit EBITDA|Net earnings per share (EPS TTM) Kineta|KA - Net earnings per share for the last four quarters|Year-over-year earnings per share growth for the last twelve months kinetabio.com|KA - Earnings per share growth this year|Earnings growth forecast for next year Kineta, Inc.
Fundamental company valuation:Kineta Bio, KA
Brand item of kinetabio.com

Investors must balance the operational risks of the biotech sector with potential returns on capital, particularly for Kineta, Inc. (KA), whose immunotherapy model is characterized by a minimal environmental footprint and a focus on laboratory safety. The projected change in earnings per share for the coming year aggregates Wall Street consensus estimates, transforming institutional expectations into a value vector that allows for an assessment of the business's fundamental resilience amid clinical trials.

Competitors of Kineta, Inc.

Expected earnings per share growth for next year IBRX|Earnings growth forecast for next year Immunocore Corp|Net earnings per share growth forecast for next year Janux Therapeutics (JANX)|arcusbio.com - Projected earnings per share growth rate for next year|Net earnings per share growth forecast for next year Zymeworks ZYME|Tango Therapeutics Inc (TNGX) - Expected net earnings per share growth next year|IOVA: Expected earnings per share growth for next year|Net earnings per one share growth forecast for next year Immatics Biotechnologies (IMTX)|XNCR (Xencor, Inc.) - Expected earnings per share growth for next year|CMPX: Projected earnings per share increase next year|REPL (Replimune) - Earnings growth forecast for next year|LYEL: Expected earnings per share trend next year|Earnings growth forecast for next year IPHA|PYXS - Expected net earnings per share growth next year|Net earnings per share growth forecast for next year Compugen CGEN|Expected earnings per share trend next year IOBT|Sutro Biopharma - Earnings growth forecast for next year|INKT - Earnings growth forecast for next year|werewolftx.com (HOWL) - Net earnings per share growth forecast for next year|Net earnings per share change forecast for next year IMMX (Immix Biopharma)|Expected earnings per share growth for next year ALXO|Expected net earnings per share growth next year cuebiopharma.com CUE|Net earnings per share growth forecast for next year PDS Biotechnology (PDSB)|Earnings growth forecast for next year sonnetbio.com (SONN)|Earnings growth forecast for next year MAIA (MAIA Biotechnology Inc)|Consensus forecast of earnings per share growth for next year Liminatus (LIMN)|LVTX - Net earnings per share growth forecast for next year|NXTC (nextcure.com) - Projected earnings per share growth rate for next year|LPTX: Earnings growth forecast for next year|Expected net earnings per share growth next year Intensity Therapeutics, Inc. (INTS)|Expected earnings per share growth for next year SNSE|TOVX (Theriva Corp) - Projected earnings per share increase next year|Earnings growth forecast for next year GRTS|Earnings growth forecast for next year neximmune.com (NEXI)|Turnstone Biologics Corp. - Expected earnings per share growth for next year|Expected earnings per share trend next year VCNX|Harpoon Tx - Earnings growth forecast for next year